Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | PRKX | P51817 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrole SCHEMBL2297382 | 0.91 | BTK (0.39) | HCAR2BTKAURKACSNK1A1DYRK1B | |
| SCHEMBL2742976 | 0.81 | HCAR2 (0.54) | HCAR2TDP1KDM4CKDM4EL3MBTL1 | |
| SCHEMBL27189220 | 0.79 | HCAR2 (0.42) | HCAR2TDP1KDM4CL3MBTL1PARP1 | |
| Urea SCHEMBL11275543 | 0.77 | MAPT (0.47) | HCAR2TDP1L3MBTL1PARP1NPC1 | |
| SCHEMBL29731607 | 0.75 | HCAR2 (0.38) | HCAR2KDM4CKDM4EL3MBTL1NPC1 | |
| SCHEMBL27239649 | 0.73 | HCAR2 (0.36) | HCAR2NPC1RAB9A | |
| SCHEMBL3344611 | 0.72 | BTK (0.46) | BTKSIRT3TDP1CDC7 | |
| SCHEMBL3342946 | 0.71 | BTK (0.43) | BTKPARP1CDC7DGAT1 | |
| SCHEMBL1504 | 0.71 | — | — | |
| SCHEMBL1623326 | 0.71 | ALDH1A1 (0.51) | KDM4EL3MBTL1NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002362-A1 | DEUTERATED 2-ARYLHETEROCYCLE-3-OXO-2,3- DIHYDROPYRIDAZINE-4-CARBOXAMIDE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI ZELGEN PHARMA.TECH CO., LTD. (CN) | 2024-01-04 | — | — | US | claimed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | claimed |
| EP-4253374-A1 | DEUTERATED 2-ARYLHETEROCYCLE-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) | 2023-10-04 | — | — | EP | claimed |
| CN-116583518-A | Deuterated 2-aromatic heterocycle-3-oxo-2, 3-dihydropyridazine-4-carboxamide inhibitor as well as preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-109863140-B | 3-oxo-2, 6-diphenyl-2, 3-dihydropyridazine-4-carboxamide | 拜耳医药股份有限公司 | 2023-02-21 | — | — | CN | claimed |
| US-20230032216-A1 | INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER | Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts Im Neuenheimer Feld 280 (DE) | 2023-02-02 | — | — | US | claimed |
| EP-4076462-A1 | COMBINATION OF AN AHR-INHIBITOR AND AN PD1-INHIBITOR ANTIBODY AND ITS USE IN THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2022-10-26 | — | — | EP | claimed |
| US-11459312-B2 | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-04 | — | — | US | claimed |
| CN-114901837-A | Interleukin-4 inducible gene 1(IL4I1) and corresponding metabolites as biomarkers for cancer | 德国癌症研究公共权益基金会 | 2022-08-12 | — | — | CN | claimed |
| CN-114786674-A | Combination of an AHR inhibitor and a PD1 inhibitor antibody and use thereof in the treatment of cancer | 拜耳公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114539221-A | Deuterated 2-heteroaromatic-3-oxo-2, 3-dihydropyridazine-4-formamide inhibitor as well as preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-114127311-A | Arene receptor (AHR) activation profile and methods for determining AHR signaling status | 德国癌症研究公共权益基金会 | 2022-03-01 | — | — | CN | claimed |
| EP-3947734-A2 | ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATION SIGNATURE AND METHODS FOR DETERMINING AHR SIGNALING STATUS | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts (DE) | 2022-02-09 | — | — | EP | claimed |
| WO-2021122434-A1 | COMBINATION OF AN AHR-INHIBITOR AND AN PD1-INHIBITOR ANTIBODY AND ITS USE IN THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-24 | — | — | WO | claimed |
| WO-2021116357-A1 | INTERLEUKIN-4-INDUCED GENE 1 (IL4I1) AND RESPECTIVE METABOLITES AS BIOMARKERS FOR CANCER | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2021-06-17 | — | — | WO | claimed |
| WO-2020201825-A2 | ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATION SIGNATURE AND METHODS FOR DETERMINING AHR SIGNALING STATUS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2020-10-08 | — | — | WO | claimed |
| US-8946225-B2 | Derivatives of 2H pyridazin-3-ones, their preparation and their use as SCD-1 inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2015-02-03 | — | — | US | claimed |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2012-07-12 | — | — | US | claimed |
| EP-2462121-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | Pierre Fabre Médicament (FR) | 2012-06-13 | — | — | EP | claimed |
| EP-0116494-B1 | PYRIDAZINE DERIVATIVES WITH A PSYCHOTROPE ACTIVITY, PROCESS FOR THEIR PREPARATION, INTERMEDIATES AND MEDICINES CONTAINING THEM | SANOFI S.A. (FR) | 1988-01-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459312-B2 | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides | AHR, ARNT, MYD88 | HCAR2 23/4885BTK 1924/4885AURKA 3058/4885 |
| US-20240002362-A1 | DEUTERATED 2-ARYLHETEROCYCLE-3-OXO-2,3- DIHYDROPYRIDAZINE-4-CARBOXAMIDE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | AHR, CYP2F1, ARNT | HCAR2 55/4885BTK 2907/4885AURKA 2008/4885 |
| US-20120178678-A1 | DERIVATIVES OF 2H PYRIDAZIN- 3 -ONES, THEIR PREPARATION AND THEIR USE AS SCD-1 INHIBITORS | SCD, SCD5, CYP2S1 | HCAR2 673/4885BTK 2370/4885AURKA 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.